ClinicalTrials.gg
CompletedNCT06649942Updated Sep 17, 2025

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

A Phase 1 interventional study of KP-001 and KP-001 in Healthy Volunteers - Male and Female, sponsored by Kaken Pharmaceutical. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Kaken Pharmaceutical · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, single-center, randomized, single-blind (participants are blinded), placebo controlled, four-way cross over TQT study (4×4 Williams square design) to investigate the effect of KP-001 on the QTc interval using open-label moxifloxacin as an active control, in adult healthy volunteers.

KP-001 and placebo (dry syrup) will be administered in blinded manner to participants, and the moxifloxacin (tablet) will be administered in open-label manner.Total duration of study participation for each participant is approximately 8 weeks.

Cardiodynamic ECG evaluations will be performed at separate locations and cardiodynamic ECG evaluators will be blinded to treatment group analyzed, ie, blinded to each of the study interventions including moxifloxacin.

Read the detailed description

This is a Phase 1, single-center, randomized, single-blind (participants are blinded), placebo controlled, four-way cross over TQT study (4×4 Williams square design) to investigate the effect of KP-001 on the QTc interval using open-label moxifloxacin as an active control, in adult healthy volunteers.

KP-001 and placebo (dry syrup) will be administered in blinded manner to participants, and the moxifloxacin (tablet) will be administered in open-label manner.

The study will comprise the following:

  • Treatment Periods 1, 2, 3, and 4: For each period, participants will be residential at the Clinical Unit from the day before the dose of study intervention (Day 1 of each treatment period) until 3 days after the dose of study intervention (Day 4 of each treatment period). Participants will receive a single dose of study intervention each period, in accordance with the assigned treatment sequence .
  • Washout: at least 7 days between administrations of each study intervention. Total duration of study participation for each participant is approximately 8 weeks.

On Day 1 of Treatment Period 1, participants will be randomly assigned in a 1:1:1:1 ratio to one of the four treatment sequences and administrated a single oral dose of one of the following four treatments under fasting condition:

  • KP-001 therapeutic dose (T): KP-001 100 mg + placebo
  • KP-001 supratherapeutic dose (ST): KP-001 400 mg
  • Placebo (P): placebo dry syrup
  • Moxifloxacin (M): moxifloxacin 400 mg tablet

Cardiodynamic ECG evaluations will be performed at separate locations and cardiodynamic ECG evaluators will be blinded to treatment group analyzed, ie, blinded to each of the study interventions including moxifloxacin.

02

Conditions studied

  • Healthy Volunteers - Male and Female

Keywords

  • Healty Adults
03

In context

Lead sponsor

Kaken Pharmaceutical is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant voluntarily agrees to participate in this study and signs an IRB-approved prior to performing any of the Screening Visit procedures.
  2. Males and females between 18 to 55 years of age, inclusive, at the Screening Visit.
  3. A female participant is eligible to participate if she is a WONCBP and is not pregnant or breastfeeding.
  4. A male participant who is sexually active with female partner(s) of must agree to use both a condom and spermicide from the first dose until 91 days after the last dose of KP-001.
  5. A male participant must agree not to donate sperm from the first dose until 91 days after the last dose of KP-001.
  6. A continuous nonsmoker who has not used nicotine-containing products for at least 3 months prior to Day -1 of Treatment Period 1 and throughout the study, based on participant self reporting and the result of cotinine test at screening and/or Day -1 of each Treatment Period.
  7. Participant is medically healthy with no abnormal screening results (eg, medical history, physical examination, laboratory profiles, vital signs, or ECGs), in the opinion of the Investigator or designee. If screening and/or admission results are abnormal, they may be repeated once at screening and/or once at admission to confirm the participant's eligibility.
  8. Participant has body weight ≥ 50.0 kg and within the range 18.0 to 30.0 kg/m2, inclusive, at screening.

Exclusion criteria

Exclusion Criteria:

  1. An uninterpretable or abnormal screening and first check-in indicating a second- or third-degree atrioventricular block, or one or more of the following: QRS interval >110 msec; >450 msec, PR interval >200 msec; HR \<40 bpm; T wave abnormalities, or any rhythm other than sinus rhythm that is interpreted by the Principal Investigator and/or qualified designee to be .
  2. History of risk factors for Torsades de Pointes, including unexplained syncope, known long QT syndrome, heart failure, myocardial infarction, angina, or clinically significant abnormal laboratory assessments including hypokalemia, hypercalcemia, or hypomagnesemia. Participants will also be excluded if there is a family history of long QT syndrome or Brugada syndrome, or family history of sudden cardiac death prior to the age of 40.
  3. A sustained supine systolic blood pressure >140 mmHg or \<90 mmHg or a supine diastolic blood pressure >90 mmHg or \<50 mmHg at screening. A sustained supine systolic blood pressure >150 mmHg or \<90 mmHg or a supine diastolic blood pressure >95 mmHg or \<50 mmHg at check-in.
  4. A resting HR of \<40 bpm or >100 bpm when vital signs are measured at screening or check in.
  5. Unstable cardiovascular disease, including recent myocardial infarction or cardiac arrhythmia.
  6. Participant is legally, mentally or physically incapacitated or, in the opinion of the Investigator, has significant mental or emotional problems, including psychiatric illness (eg, depression and/or anxiety) at the time of the Screening Visit, or that could reasonably be expected to develop during the conduct of the study.
  7. Participant has a significant history or clinical manifestation of any metabolic, allergic, dermatologic, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder as determined by the Investigator or designee.
  8. Participant has a history of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
  9. Participant used any prescription or non-prescription medications (including vitamins, recreational drugs, and dietary or herbal supplements) within 14 days or five half-lives (whichever is longer) prior to Day -1 of Treatment Period 1 and until completion of the Follow-up Call unless, in the opinion of the Investigator, may be treatment for an AE or will not interfere with the interpretation of safety.
  10. Participant underwent blood donation or transfusion within 56 days prior to Day -1 of Treatment Period 1 and throughout the study.
  11. Participant has a history or presence of or idiosyncratic reaction to any components of the KP-001 formulation or any components of formulation used as study intervention during the study.
  12. Participant has enrolled in a previous clinical study with KP-001 medication.
  13. Participant has a history of drug or alcohol abuse (regular alcohol consumption exceeding 14 drinks/week [1 drink = 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of hard liquor] within one year before the Screening Visit).
  14. Participant has a complication of drug allergies or history of drug allergies.
  15. Participant used any drug in the last 30 days or five half-lives (if known), whichever is longer, prior to Day -1 of Treatment Period 1.
  16. Participant had any major illness within 30 days before the Screening Visit.
  17. Participant had any major surgical procedure within 30 days prior to Day -1 of Treatment Period 1 or any planned surgery during study period.
  18. Participant had any laboratory abnormality that, in the judgment of the Investigator, would put the participant at unacceptable risk for participation in the study or may interfere with the assessments included in the study.
  19. Participant has abnormal findings on the screening ECG deemed clinically significant by the Investigator or qualified designee.
  20. Participant is an employee of the Sponsor or any CRO involved in the study, the Investigator, or an immediate family member (partner, offspring, parents, siblings, or sibling's offspring) of an employee involved in the study.
  21. Participant has consumed alcohol- or caffeine-containing foods and beverages within 72 hours prior to Day -1 of Treatment Period 1 and does not agree to refrain from consuming during the entire study, unless deemed acceptable by the Investigator.
  22. Participant has positive urine drug or urine alcohol and positive cotinine test results at screening or Day -1 of Treatment Period 1.
  23. Participant has consumed grapefruit-containing foods and beverages within 7 days prior to Day -1 of Treatment Period 1 and does not agree to refrain from consuming during the entire study.
  24. Participant has consumed St. John's wort-containing foods and beverages within 14 days prior to Day -1 of Treatment Period 1 and does not agree to refrain from consuming during the entire study.
  25. Participant is unable or unwilling to undergo multiple venipunctures.
  26. Participant has a history or presence of liver disease or cholecystectomy within one year prior to screening.
  27. Participant has an >5.7% at screening.
  28. Participant has positive results at screening for , core antibody, hepatitis B surface antigen or virus.
  29. Participant has a disorder or any condition that would interfere with the absorption, distribution, metabolism, or excretion of drugs.
  30. Participant has calculated using the CKD-EPI formula \<80 mL/min at screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Treatment T

    KP-001 therapeutic dose (KP-001 100 mg + placebo)

    Drug: KP-001

  • Experimental
    Treatment ST

    KP-001 supratherapeutic dose (KP-001 400 mg)

    Drug: KP-001

  • Active comparator
    Treatment M

    moxifloxacin 400 mg

    Drug: Moxifloxacin 400 mg

  • Placebo comparator
    Treatment P

    placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Largest time-matched placebo-corrected change from baseline in QTcF (ΔΔQTcF) collected in a 24-hour period after KP-001 single dosing

    To evaluate the effect of KP-001 as single therapeutic and supratherapeutic dose on the QTcF interval

    Time frame: Before dosing (Baseline) through 24 hours

Secondary outcomes

  1. Placebo-corrected change from baseline in QTcF (ΔΔQTcF)

    To study the concentration-response relationship between KP-001 concentrations after dosing and ΔQTcF (C-ΔQTcF model)

    Time frame: Before dosing (Baseline) through 24 hours

  2. Largest time-matched placebo-corrected change from baseline in QTcF (ΔΔQTcF) after moxifloxacin dosing

    Largest time-matched placebo-corrected change from baseline in QTcF (ΔΔQTcF) collected in a 24-hour period after moxifloxacin dosing

    Time frame: Before dosing (Baseline) through 24 hours

  3. Categorial outliers for QRS after KP-001 dosing

    Time frame: Before dosing (Baseline) through 24 hours

  4. Placebo-corrected ΔHR after KP-001 dosing

    Time frame: Before dosing (Baseline) through 24 hours

  5. Placebo-corrected ΔPR after KP-001 dosing

    Time frame: Before dosing (Baseline) through 24 hours

  6. Placebo-corrected ΔQRS after KP-001 dosing

    Time frame: Before dosing (Baseline) through 24 hours

  7. Categorial outliers for PR after KP-001 dosing

    Time frame: Before dosing (Baseline) through 24 hours

  8. Categorial outliers for HR after KP-001 dosing

    Time frame: Before dosing (Baseline) through 24 hours

  9. Categorial outliers for QTcF after KP-001 dosing

    Time frame: Before dosing (Baseline) through 24 hours

  10. Change from baseline PR after KP-001 dosing

    Time frame: Before dosing (Baseline) through 24 hours

  11. Change from baseline HR after KP-001 dosing

    Time frame: Before dosing (Baseline) through 24 hours

  12. PK parameters of KP-001 in plasma: CLtot/F

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 36 and 72 hours post-dose

  13. PK parameters of KP-001 in plasma: Tmax

    To evaluate PK of KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose

  14. PK parameters of KP-001 in plasma: t1/2

    To evaluate PK of KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose

  15. PK parameters of KP-001 in plasma: Vz/F

    To evaluate PK of KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose

  16. Frequency of treatment-emergent morphology and appearance of U-wave after KP-001 dosing

    Time frame: Before dosing (Baseline) through 24 hours

  17. PK parameters of KP-001 in plasma: Cmax

    To evaluate PK of KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose

  18. Frequency of treatment-emergent changes in Twave morphology after KP-001 dosing

    Time frame: Before dosing (Baseline) through 24 hours

  19. PK parameters of KP-001 in plasma: AUC0-24

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose

  20. PK parameters of KP-001 in plasma: AUC0-48

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose

  21. PK parameters of KP-001 in plasma: AUC0-72

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose

  22. PK parameters of KP-001 in plasma: AUCinf

    Area Under the Concentration Time-curve From Time Zero to Infinity for KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose

  23. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) predicted from the C-ΔQTcF model at Cmax

    To study the concentration-response relationship between KP-001 concentrations

    Time frame: Before dosing (Baseline) through 24 hours

07

Study locations

1 site
  • Parexel Early Phase Clinical Unit - Los Angeles
    Glendale, California 91206, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Mar 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2024
First posted
Oct 21, 2024
StartActual
Oct 1, 2024
Primary completionActual
Mar 24, 2025
CompletionActual
Mar 24, 2025
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06649942
Lead sponsor
Kaken Pharmaceutical
Collaborators
Parexel
Responsible party
Sponsor
First posted
Oct 21, 2024
Start date
Oct 1, 2024
Primary completion
Mar 24, 2025
Completion
Mar 24, 2025
Last update
Sep 17, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KP-001

Start the discussion